Table 1 Demographic characteristics of the four study groups
Variable | Normal LA size (16–34 ml/m2, n = 507) | Mild LAE (35–41 ml/m2, n = 134) | Moderate LAE (42–48 ml/m2, n = 51) | Severe LAE (> 48 ml/m2, n = 23) | P |
|---|---|---|---|---|---|
Age (years) | 65.96 ± 9.11 | 67.75 ± 8.39 | 67.55 ± 7.16 | 70.65 ± 7.90 | 0.016 |
Gender, male | 47.73% | 48.51% | 62.75% | 65.22% | 0.088 |
BSA (m2) | 1.84 ± 0.16 | 1.82 ± 0.16 | 1.87 ± 0.18 | 1.85 ± 0.14 | 0.357 |
BMI (kg/m2) | 25.56 ± 3.29 | 25.50 ± 3.27 | 25.57 ± 3.72 | 25.32 ± 3.12 | 0.986 |
SBP (mmHg)* | 171.41 ± 19.06 | 177.13 ± 18.50 | 172.13 ± 21.24 | 184.74 ± 18.37 | 0.002 |
DBP (mmHg)* | 98.83 ± 17.31 | 97.72 ± 17.39 | 97.11 ± 22.04 | 100.79 ± 18.05 | 0.814 |
HR (beats/min) | 71.07 ± 10.94 | 66.46 ± 10.58 | 65.67 ± 8.93 | 62.13 ± 8.74 | < 0.001 |
CHD | 7.50% | 12.69% | 13.73% | 13.40% | 0.144 |
Stroke | 20.71% | 17.91% | 25.49% | 34.78% | 0.256 |
Peripheral vascular disease | 8.09% | 8.96% | 11.76% | 13.04% | 0.705 |
HT | 76.73% | 90.30% | 88.24% | 82.61% | 0.002 |
Diabetes mellitus | 31.95% | 25.37% | 31.37% | 17.39% | 0.257 |
Smoking | 33.53% | 28.36% | 43.14% | 47.83% | 0.122 |
Obesity | 20.32% | 20.90% | 21.57% | 17.39% | 0.979 |
Dyslipidemia | 49.11% | 52.24% | 52.94% | 34.78% | 0.446 |
Aspirin | 51.48% | 50.00% | 35.29% | 47.83% | 0.179 |
ACEI | 7.30% | 5.97% | 7.84% | 4.35% | 0.898 |
ARB | 3.36% | 4.48% | 5.88% | 13.04% | 0.117 |
Calcium antagonists | 39.25% | 44.78% | 33.33% | 43.48% | 0.484 |
βblockers | 6.71% | 9.02% | 9.80% | 17.39% | 0.223 |
Statins | 0.99% | 0.00% | 3.92% | 4.55% | 0.056 |
Diuretics | 3.35% | 0.75% | 5.88% | 4.35% | 0.257 |